Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Radius-X: An Expanded Treatment Protocol of Midostaurin in Adults with Newly Diagnosed FLT3 -Mutation-Positive Acute Myeloid Leukemia Eligible for Standard Chemotherapy

Gail J. Roboz, MD, Stephen A. Strickland, MD MSCI, Mark R. Litzow, MD, Andrew Dalovisio, MD, Alexander E. Perl, MD, Gaetano Bonifacio, MD, Kelly Haines, Alysha Barbera, Das Purkayastha, Kendra Sweet, MD

Blood (2017) 130 (Supplement 1): 1338.

https://doi.org/10.1182/blood.V130.Suppl_1.1338.1338

Published: 2017

Journal Articles

Cost-Effectiveness of Midostaurin in the Treatment of Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia in the United States

Eytan M. Stein, MD, Jipan Xie, MD PhD, Emilie Duchesneau, Subrata Bhattacharyya, PhD, Briana Ndife, MPH, Gaetano Bonifacio, MD, George J Joseph, BPharm, MS, PhD

Blood (2017) 130 (Supplement 1): 4703.

https://doi.org/10.1182/blood.V130.Suppl_1.4703.4703

Published: 2017

Journal Articles

Real-World Treatment Patterns, Healthcare Resource Utilization, and Costs in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)

Eytan M. Stein, MD, Dominick Latremouille-Viau, MSc, Annie Guerin, MSc, Sherry Shi, MSc, Patrick Gagnon-Sanschagrin, BSc, Gaetano Bonifacio, MD, George J Joseph, BPharm, MS, PhD

Blood (2016) 128 (22): 5929.

https://doi.org/10.1182/blood.V128.22.5929.5929

Published: 2016

Journal Articles

Radius: A Phase 2, Randomized Trial of Standard of Care (SOC) with or without Midostaurin to Prevent Relapse Following Allogeneic Hematopoietic Stem Cell Transplant (alloHSCT) in Patients (pts) with FLT3 -Itd-Mutated Acute Myeloid Leukemia (AML)

Richard T. Maziarz, MD, Mrinal M Patnaik, MBBS, Bart L. Scott, MD, Sanjay R. Mohan, MD, Abhinav Deol, MD, Scott D. Rowley, MD FACP, Dennis Dong Hwan Kim, MD PhD, Kelly Haines, BS, Gaetano Bonifacio, MD, Patrice Rine, Hugo F. Fernandez, MD

Blood (2016) 128 (22): 2248.

https://doi.org/10.1182/blood.V128.22.2248.2248

Published: 2016

Journal Articles

ENESTnext Final Results: Deep Molecular Response (MR) with Nilotinib (NIL) in Patients (pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP)

Jesus G. Berdeja, MD, Michael Heinrich, Shaker Dakhil, MD FACP, Stuart L. Goldberg, MD, Martha Wadleigh, MD, Rosalind Catchatourian, MD, Philip Kuriakose, MD, Jorge E. Cortes, MD, Jerald P. Radich, David A. Rizzieri, MD, Gaetano Bonifacio, MD, Ilva Dautaj, Ghulam Warsi, PhD, Michael J. Mauro, MD

Blood (2015) 126 (23): 4048.

https://doi.org/10.1182/blood.V126.23.4048.4048

Published: 2015

Journal Articles

Palifermin in Patients with Hematological Malignancies Undergoing Autologous Hematopoietic Stem Cell Transplantation (HSCT): The Italian Early Access Program (EAP).

Laura M. Cavagna, MD, Gaetano Bonifacio, MD, Emanuele Angelucci, MD, Alessandro Fanni, MD, Giuseppe Milone, MD, Eugenio Gallo, MD, Elena Benincasa, MD

Blood (2006) 108 (11): 5236.

https://doi.org/10.1182/blood.V108.11.5236.5236

Published: 2006

NARROW

Radius-X: An Expanded Treatment Protocol of Midostaurin in Adults with Newly Diagnosed FLT3 -Mutation-Positive Acute Myeloid Leukemia Eligible for Standard Chemotherapy

Cost-Effectiveness of Midostaurin in the Treatment of Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia in the United States

Real-World Treatment Patterns, Healthcare Resource Utilization, and Costs in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)

Radius: A Phase 2, Randomized Trial of Standard of Care (SOC) with or without Midostaurin to Prevent Relapse Following Allogeneic Hematopoietic Stem Cell Transplant (alloHSCT) in Patients (pts) with FLT3 -Itd-Mutated Acute Myeloid Leukemia (AML)

ENESTnext Final Results: Deep Molecular Response (MR) with Nilotinib (NIL) in Patients (pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP)

Palifermin in Patients with Hematological Malignancies Undergoing Autologous Hematopoietic Stem Cell Transplantation (HSCT): The Italian Early Access Program (EAP).

Email alerts

ASH Publications

American Society of Hematology

Radius-X: An Expanded Treatment Protocol of Midostaurin in Adults with Newly Diagnosed FLT3 -Mutation-Positive Acute Myeloid Leukemia Eligible for Standard Chemotherapy

Cost-Effectiveness of Midostaurin in the Treatment of Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia in the United States

Real-World Treatment Patterns, Healthcare Resource Utilization, and Costs in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)

Radius: A Phase 2, Randomized Trial of Standard of Care (SOC) with or without Midostaurin to Prevent Relapse Following Allogeneic Hematopoietic Stem Cell Transplant (alloHSCT) in Patients (pts) with FLT3 -Itd-Mutated Acute Myeloid Leukemia (AML)

ENESTnext Final Results: Deep Molecular Response (MR) with Nilotinib (NIL) in Patients (pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP)

Palifermin in Patients with Hematological Malignancies Undergoing Autologous Hematopoietic Stem Cell Transplantation (HSCT): The Italian Early Access Program (EAP).

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only